Market Cap 11.88B
Revenue (ttm) 3.81B
Net Income (ttm) 663.00M
EPS (ttm) N/A
PE Ratio 17.62
Forward PE 20.78
Profit Margin 17.40%
Debt to Equity Ratio 0.16
Volume 365,700
Avg Vol 1,125,936
Day's Range N/A - N/A
Shares Out 834.94M
Stochastic %K 46%
Beta 0.39
Analysts Hold
Price Target $16.20

Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equival...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 91 40 4900 2900
Address:
8-2-337, Road No. 3, Banjara Hills, Hyderabad, India
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 24 at 8:50 PM
$RDY RSI: 48.39, MACD: 0.0489 Vol: 0.13, MA20: 14.04, MA50: 14.00 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Kv113
Kv113 Dec. 24 at 4:50 PM
$RDY $RDY Thesis: Stock is in cosolidation as long as it stays in consolidation above VWAP lower good to hold and wait for breakout
0 · Reply
An1hi_Villalobos
An1hi_Villalobos Dec. 16 at 4:40 PM
$RDY SBFM revenue growth in a bear market is the flex
0 · Reply
SparkyReturns
SparkyReturns Dec. 8 at 4:33 PM
$BIIB I'm surprised some of the large drug companies haven't noticed what ICU is doing.... Check out this investing idea. * ICU * What other company has a market cap of only $12 Million but is launching a product with an annual market in the 10s of BILLIONS? [Read that again = 1000x] Patients' lives are saved and eliminates $100K/ year of dialysis dependency; Device has broad application for over a half dozen critical conditions (kidney, heart, ARDS, Sepsis, Covid, burns, etc); The device "sells itself" by saving hospitals $40K per average stay; Insurers will love it because their costs will go down; Government will love it to reduce number of Medicare patients on lifetime dialysis; FDA seems to be fast tracking all decisions, already gave grants; ZERO DEBT, and revenue ramping up. This may be the best time to get in to ICU for those looking for an investing idea. Cheers! $SNY $TAK $RDY $TEVA
0 · Reply
BioTuesdays
BioTuesdays Dec. 8 at 2:40 PM
$IMMP and $RDY have announced that they have entered into a strategic collaboration and exclusive licensing agreement for the development and commercialization of the oncology drug Eftilagimod Alfa (efti)—in all countries outside North America, Europe, Japan, and Greater China https://biotuesdays.com/2025/12/08/immutep-and-dr-reddys-labs-collaborate-to-commercialize-oncology-drug/
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 4 at 2:23 AM
$RDY Current Stock Price: $14.12 Contracts to trade: $15 RDY Dec 19 2025 Call Entry: $0.10 Exit: $0.19 ROI: 90% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BigBreakingWire
BigBreakingWire Nov. 9 at 6:01 AM
Dr. Reddy’s Laboratories Hit by ₹2.16 Crore Cyber Fraud — Key Points: Dr. Reddy’s Laboratories lost ₹2.16 crore after transferring funds to a fraudulent account. Hackers impersonated Group Pharmaceutical Ltd. executives using a spoofed email — ‘[email protected]’ (fake) instead of ‘[email protected]’ (real). The fraudsters gained access to genuine email communication between both companies. The payment was diverted to a fake Bank of Baroda account. Group Pharmaceutical filed an FIR with Bengaluru City Cyber Crime Police, seeking freezing and recovery of funds. The case was registered under IT Act sections for identity theft and cheating by personation, with the accused located in Vadodara, Gujarat. $DRREDDY.NSE $RDY $NIFTY50.NSE
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 30 at 2:40 PM
$RDY Share Price: $13.48 Contract Selected: Jun 18, 2026 $15 Calls Buy Zone: $0.17 – $0.21 Target Zone: $0.27 – $0.33 Potential Upside: 52% ROI Time to Expiration: 230 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ZacksResearch
ZacksResearch Oct. 27 at 4:19 PM
$RDY beats earnings estimates — but why is the stock still struggling? Shares have fallen 7.6% YTD despite a 9.8% revenue boost, primarily driven by global generics revenues. 🇪🇺 Positive CHMP opinion for AVT03 biosimilar could significantly impact future revenue if approved by the European Commission. Full analysis here 👉 https://www.zacks.com/stock/news/2778024/dr-reddys-q2-earnings-beat-estimates-generics-sales-boost-revenues?cid=sm-stocktwits-2-2778024-body-17810&ADID=SYND_STOCKTWITS_TWEET_2_2778024_BODY_17810
0 · Reply
ZacksResearch
ZacksResearch Oct. 27 at 3:19 PM
$RDY beats Q2 expectations — generics power the surge Strong global generics demand lifted both earnings and revenue, while new launches and biosimilar progress are fueling future momentum. Full Q2 breakdown and growth drivers here 👉 https://www.zacks.com/stock/news/2778024/dr-reddys-q2-earnings-beat-estimates-generics-sales-boost-revenues?cid=sm-stocktwits-2-2778024-teaser-17780&ADID=SYND_STOCKTWITS_TWEET_2_2778024_TEASER_17780
0 · Reply
Latest News on RDY
Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds

Oct 29, 2025, 2:02 PM EDT - 2 months ago

Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds


Dr. Reddy's Q1FY26 Financial Results

Jul 23, 2025, 1:46 PM EDT - 5 months ago

Dr. Reddy's Q1FY26 Financial Results


Dr. Reddy's Continues To Be A Good Buy At Current Valuation

May 15, 2025, 11:47 AM EDT - 7 months ago

Dr. Reddy's Continues To Be A Good Buy At Current Valuation


Dr. Reddy's Q4 & Full Year FY25 Financial Results

May 9, 2025, 2:53 PM EDT - 8 months ago

Dr. Reddy's Q4 & Full Year FY25 Financial Results


Dr. Reddy's Q3 & 9MFY25 Financial Results

Jan 23, 2025, 12:35 PM EST - 11 months ago

Dr. Reddy's Q3 & 9MFY25 Financial Results


Dr. Reddy's Q2 & H1FY25 Financial Results

Nov 5, 2024, 9:59 AM EST - 1 year ago

Dr. Reddy's Q2 & H1FY25 Financial Results


Dr. Reddy's Q1FY25 Financial Results

Jul 27, 2024, 9:51 AM EDT - 1 year ago

Dr. Reddy's Q1FY25 Financial Results


Dr. Reddy's Q4 & Full Year FY24 Financial Results

May 7, 2024, 10:31 AM EDT - 1 year ago

Dr. Reddy's Q4 & Full Year FY24 Financial Results


Dr. Reddy's Q3 & 9M FY24 Financial Results

Jan 31, 2024, 9:44 AM EST - 2 years ago

Dr. Reddy's Q3 & 9M FY24 Financial Results


OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 24 at 8:50 PM
$RDY RSI: 48.39, MACD: 0.0489 Vol: 0.13, MA20: 14.04, MA50: 14.00 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Kv113
Kv113 Dec. 24 at 4:50 PM
$RDY $RDY Thesis: Stock is in cosolidation as long as it stays in consolidation above VWAP lower good to hold and wait for breakout
0 · Reply
An1hi_Villalobos
An1hi_Villalobos Dec. 16 at 4:40 PM
$RDY SBFM revenue growth in a bear market is the flex
0 · Reply
SparkyReturns
SparkyReturns Dec. 8 at 4:33 PM
$BIIB I'm surprised some of the large drug companies haven't noticed what ICU is doing.... Check out this investing idea. * ICU * What other company has a market cap of only $12 Million but is launching a product with an annual market in the 10s of BILLIONS? [Read that again = 1000x] Patients' lives are saved and eliminates $100K/ year of dialysis dependency; Device has broad application for over a half dozen critical conditions (kidney, heart, ARDS, Sepsis, Covid, burns, etc); The device "sells itself" by saving hospitals $40K per average stay; Insurers will love it because their costs will go down; Government will love it to reduce number of Medicare patients on lifetime dialysis; FDA seems to be fast tracking all decisions, already gave grants; ZERO DEBT, and revenue ramping up. This may be the best time to get in to ICU for those looking for an investing idea. Cheers! $SNY $TAK $RDY $TEVA
0 · Reply
BioTuesdays
BioTuesdays Dec. 8 at 2:40 PM
$IMMP and $RDY have announced that they have entered into a strategic collaboration and exclusive licensing agreement for the development and commercialization of the oncology drug Eftilagimod Alfa (efti)—in all countries outside North America, Europe, Japan, and Greater China https://biotuesdays.com/2025/12/08/immutep-and-dr-reddys-labs-collaborate-to-commercialize-oncology-drug/
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 4 at 2:23 AM
$RDY Current Stock Price: $14.12 Contracts to trade: $15 RDY Dec 19 2025 Call Entry: $0.10 Exit: $0.19 ROI: 90% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BigBreakingWire
BigBreakingWire Nov. 9 at 6:01 AM
Dr. Reddy’s Laboratories Hit by ₹2.16 Crore Cyber Fraud — Key Points: Dr. Reddy’s Laboratories lost ₹2.16 crore after transferring funds to a fraudulent account. Hackers impersonated Group Pharmaceutical Ltd. executives using a spoofed email — ‘[email protected]’ (fake) instead of ‘[email protected]’ (real). The fraudsters gained access to genuine email communication between both companies. The payment was diverted to a fake Bank of Baroda account. Group Pharmaceutical filed an FIR with Bengaluru City Cyber Crime Police, seeking freezing and recovery of funds. The case was registered under IT Act sections for identity theft and cheating by personation, with the accused located in Vadodara, Gujarat. $DRREDDY.NSE $RDY $NIFTY50.NSE
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 30 at 2:40 PM
$RDY Share Price: $13.48 Contract Selected: Jun 18, 2026 $15 Calls Buy Zone: $0.17 – $0.21 Target Zone: $0.27 – $0.33 Potential Upside: 52% ROI Time to Expiration: 230 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ZacksResearch
ZacksResearch Oct. 27 at 4:19 PM
$RDY beats earnings estimates — but why is the stock still struggling? Shares have fallen 7.6% YTD despite a 9.8% revenue boost, primarily driven by global generics revenues. 🇪🇺 Positive CHMP opinion for AVT03 biosimilar could significantly impact future revenue if approved by the European Commission. Full analysis here 👉 https://www.zacks.com/stock/news/2778024/dr-reddys-q2-earnings-beat-estimates-generics-sales-boost-revenues?cid=sm-stocktwits-2-2778024-body-17810&ADID=SYND_STOCKTWITS_TWEET_2_2778024_BODY_17810
0 · Reply
ZacksResearch
ZacksResearch Oct. 27 at 3:19 PM
$RDY beats Q2 expectations — generics power the surge Strong global generics demand lifted both earnings and revenue, while new launches and biosimilar progress are fueling future momentum. Full Q2 breakdown and growth drivers here 👉 https://www.zacks.com/stock/news/2778024/dr-reddys-q2-earnings-beat-estimates-generics-sales-boost-revenues?cid=sm-stocktwits-2-2778024-teaser-17780&ADID=SYND_STOCKTWITS_TWEET_2_2778024_TEASER_17780
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 6 at 8:22 PM
$RDY Really good write-up that perfectly summarizes RDY's present situation. So if you want to bring your RDY knowledge up to date or just discover RDY, this is required reading. https://beyondspx.com/quote/RDY/analysis/dr-reddy-s-innovation-and-diversification-powering-future-growth-amidst-generic-headwinds-rdy
0 · Reply
ZacksResearch
ZacksResearch Oct. 6 at 2:21 PM
$ESPR surged 13.8% on settlement news with $RDY! 🚀 Esperion clinched a deal preventing RDY’s generic launches of Nexletol/Nexlizet until 2040, except under certain conditions, resolving patent disputes and boosting investor confidence. 📈 With a 50% YTD rise, ESPR is outpacing the industry’s 14.1% growth. Find out what this means for future growth 👉 https://www.zacks.com/stock/news/2762841/espr-settles-nexletolnexlizet-patent-litigation-with-rdy-stock-up?cid=sm-stocktwits-2-2762841-body-14760&ADID=SYND_STOCKTWITS_TWEET_2_2762841_BODY_14760
1 · Reply
WallStWireAds
WallStWireAds Aug. 30 at 12:22 PM
$DRREDDY.NSE $RDY https://capnotes.beehiiv.com/p/dr-reddy-s-multi-lever-strategy-to-power-its-next-phase-of-growth
0 · Reply
G101SPM
G101SPM Aug. 7 at 10:45 AM
#NOISE According to SPM tag, India Prime Minister Narendra Modi says he will not compromise on tariffs. In-play: $RDY, $INFY, $WIT, $INDA
0 · Reply
WallStWireAds
WallStWireAds Aug. 2 at 3:45 PM
$RDY https://alphacatalyst.beehiiv.com/p/dr-reddy-s-reports-record-revenues-in-q1-signals-steady-execution-through-transition-year
0 · Reply
SparkyReturns
SparkyReturns Jul. 31 at 2:43 PM
$TEVA Thought you might like to see. $INCY $GMAB $RDY $NBIX
0 · Reply
Flrz
Flrz Jul. 26 at 8:21 AM
0 · Reply
ZacksResearch
ZacksResearch Jul. 24 at 4:23 PM
$RDY Q1 earnings beat — but is the stock a buy? EPS of 20 cents per ADS topped the Zacks Consensus Estimate of 18 cents. Revenues grew 11% year over year to $997 million, driven by growth in global generics revenues, surpassing estimates. Yet, shares have slipped 7.5% year to date. Understand the risks before investing in RDY 👉 https://www.zacks.com/stock/news/2613023/dr-reddys-q1-earnings-beat-estimates-generics-sales-boost-revenues?cid=sm-stocktwits-2-2613023-body-3688&ADID=SYND_STOCKTWITS_TWEET_2_2613023_BODY_3688
0 · Reply
ZacksResearch
ZacksResearch Jul. 24 at 2:34 PM
$RDY beats Q1 estimates — generics driving the surge Earnings and revenue both came in above expectations, powered by strong growth in global generic sales. See what could drive RDY’s next move 👉 https://www.zacks.com/stock/news/2613023/dr-reddys-q1-earnings-beat-estimates-generics-sales-boost-revenues?cid=sm-stocktwits-2-2613023-teaser-3564&ADID=SYND_STOCKTWITS_TWEET_2_2613023_TEASER_3564
0 · Reply
XkaliburTrading
XkaliburTrading Jul. 23 at 6:46 PM
$RDY https://benzinga.com/node/46581767
0 · Reply
WallStWireAds
WallStWireAds Jul. 18 at 3:45 PM
$RDY $DRREDDY.NSE https://thefinanceherald.com/expanding-the-preventive-care-frontier-dr-reddys-launches-sanofis-beyfortus-in-india/
0 · Reply